These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7934365)

  • 21. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
    Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
    Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
    [No Abstract]   [Full Text] [Related]  

  • 22. Fibrate treatment can increase serum creatinine levels.
    Tsimihodimos V; Kakafika A; Elisaf M
    Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
    [No Abstract]   [Full Text] [Related]  

  • 23. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E; Miltiadous G; Elisaf M
    Diabetes Obes Metab; 2001 Apr; 3(2):97-8. PubMed ID: 11298731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatinine rise after fibrate therapy in renal graft recipients.
    Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C
    Lancet; 1993 Mar; 341(8848):840. PubMed ID: 8096050
    [No Abstract]   [Full Text] [Related]  

  • 26. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
    Raslová K; Nagyová A; Dobiásová M; Ptácková K; Dusinská M
    Acta Diabetol; 2000; 37(3):131-4. PubMed ID: 11277313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrates and HDL cholesterol.
    Murphy MJ; Packard CJ; O'Reilly DS
    Ann Clin Biochem; 1997 Jan; 34 ( Pt 1)():114. PubMed ID: 9022900
    [No Abstract]   [Full Text] [Related]  

  • 29. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 31. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
    Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 34. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.
    Lupp A; Karge E; Danz M; Deufel T; Oelschläger H; Klinger W
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):203-18. PubMed ID: 16250258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.